FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs.

Research Grants 15 show all


$100K
2003

$187.5K
2004

$295.9K
2006

$497.1K
2007

$673.3K
2009

Publications 119 show all

  • 9
    Glycine/analogs & derivatives
  • 8
    Isoquinolines/therapeutic use
  • 7
    Anemia/drug therapy
  • 7
    Hypoxia-Inducible Factor-Proline Dioxygenases/antagonists & inhibitors
  • 6
    Connective Tissue Growth Factor/antagonists & inhibitors
  • 5
    Connective Tissue Growth Factor/metabolism
  • 5
    Renal Insufficiency, Chronic/complications
  • 4
    Antibodies, Monoclonal/pharmacology
  • 4
    Connective Tissue Growth Factor/genetics
  • 4
    Fibroblasts/metabolism

Patents 793show all

  • 288
    A61K - Preparations for medical, dental, or toilet purposes
  • 179
    C07K - Peptides
  • 111
    C07D - Heterocyclic compounds
  • 57
    C12N - Microorganisms or enzymes
  • 50
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 22
    C08L - Compositions of macromolecular compounds
  • 17
    A23L - Foods, foodstuffs, or non-alcoholic beverages, not covered by subclasses  -
  • 17
    A61Q - Specific use of cosmetics or similar toilet preparations
  • 17
    C08H - Derivatives of natural macromolecular compounds
  • 17
    G03C - Photosensitive materials for photographic purposes

Clinical Trials 64show all

30Phase 315Phase 214Phase 15Other

SEC Filings show all


83
8-K

15
10-Q

5
10-K

2
D

1
S-1

Contact Information

409 Illinois St.
San Francisco, CA 94158
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$188,023,000251-5002016-07-08Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2014-11-19$20,000,000Series Unknown
2012-07-27$6,023,000Private Equity
2005-02-17$100,000,000Series UnknownAdage Capital ManagementMerlin Biomed, Daiwa SMBC Capital, BioFund Management, Goldman Sachs, T. Rowe Price, Sigma Capital Group, Och-Ziff Capital Management, Brookside Capital, Duquesne Capital Management, Corriente Biotechnology Partners, Apothecary Capital, Rosewood Corporation, Astellas Pharma
2016-07-08$62,000,000Post Ipo EquityAstraZeneca

SEC Form D Funding Events

DateOfferedSoldType
2014-12-10$20,000,000$20,000,000Equity
2007-04-11Unknown Unknown Other (Paper Filing)

Key Executives

  • Thomas B. Neff
    Executive Officer, Director
  • Pat Cotroneo
    Executive Officer
  • Frank H. Valone
    Executive Officer
  • K. Peony Yu
    Executive Officer
  • Thomas F. Kearns
    Director
  • Kalevi Kurkijarvi
    Director
  • Miguel Madero
    Director
  • Rory B. Riggs
    Director
  • Roberto Pedro Rosenkranz
    Director
  • Jorma Routti
    Director
  • James A. Schoeneck
    Director
  • Julian N. Stern
    Director
  • Toshinari Tamura
    Director